Summary
The aim of ‘AMNIOGEL’ is the development of human extracellular matrix (ECM) based materials, as radically innovative,
highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establishment. In
particular, we will develop 3D disease models that could be used as an enabling tool for personalized drug discovery,
increasing our understanding of the mechanisms behind bone cancer.
The proposed cutting-edge technology enables the culture of human cells in a physiologically relevant microenvironment for
applications in cell culture research, drug screening and development, cancer research, tissue engineering, replacement of
animal testing and therapeutic applications. The potential of this technology to reduce or completely replace use of animals
for biological screenings is expected to have a significant impact in the 3D cell culture market and pharmaceutical industry
by accelerating drug screening and development reducing associated costs. The innovation potential of our products is
based on the fact that contain human biochemical cues (vital for cell function), is a complete xeno-free solution (avoids
contamination) for human cell culture and easy to manipulate. It is worth mentioning that offers the possibility to be
personalised (using the patient’s own ECM) according to the customer needs. Moreover, our culture substrates are easily
processed in multiple geometries and in microarrays amenable to ‘organ-on- a-chip’ systems designed for high-throughput
screening (HTS) applications.
highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establishment. In
particular, we will develop 3D disease models that could be used as an enabling tool for personalized drug discovery,
increasing our understanding of the mechanisms behind bone cancer.
The proposed cutting-edge technology enables the culture of human cells in a physiologically relevant microenvironment for
applications in cell culture research, drug screening and development, cancer research, tissue engineering, replacement of
animal testing and therapeutic applications. The potential of this technology to reduce or completely replace use of animals
for biological screenings is expected to have a significant impact in the 3D cell culture market and pharmaceutical industry
by accelerating drug screening and development reducing associated costs. The innovation potential of our products is
based on the fact that contain human biochemical cues (vital for cell function), is a complete xeno-free solution (avoids
contamination) for human cell culture and easy to manipulate. It is worth mentioning that offers the possibility to be
personalised (using the patient’s own ECM) according to the customer needs. Moreover, our culture substrates are easily
processed in multiple geometries and in microarrays amenable to ‘organ-on- a-chip’ systems designed for high-throughput
screening (HTS) applications.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/957585 |
| Start date: | 01-09-2020 |
| End date: | 31-10-2022 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
The aim of ‘AMNIOGEL’ is the development of human extracellular matrix (ECM) based materials, as radically innovative,highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establishment. In
particular, we will develop 3D disease models that could be used as an enabling tool for personalized drug discovery,
increasing our understanding of the mechanisms behind bone cancer.
The proposed cutting-edge technology enables the culture of human cells in a physiologically relevant microenvironment for
applications in cell culture research, drug screening and development, cancer research, tissue engineering, replacement of
animal testing and therapeutic applications. The potential of this technology to reduce or completely replace use of animals
for biological screenings is expected to have a significant impact in the 3D cell culture market and pharmaceutical industry
by accelerating drug screening and development reducing associated costs. The innovation potential of our products is
based on the fact that contain human biochemical cues (vital for cell function), is a complete xeno-free solution (avoids
contamination) for human cell culture and easy to manipulate. It is worth mentioning that offers the possibility to be
personalised (using the patient’s own ECM) according to the customer needs. Moreover, our culture substrates are easily
processed in multiple geometries and in microarrays amenable to ‘organ-on- a-chip’ systems designed for high-throughput
screening (HTS) applications.
Status
CLOSEDCall topic
ERC-2020-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
